Brolucizumab
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Brolucizumab |
| DrugBank ID | DB14864 |
| Brand Names (EU) | Beovu |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.67% |
Approved Indication (EMA)
Beovu is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (AMD).
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies | 99.67% | DL |
| 2 | esophageal varices without bleeding | 99.12% | DL |
| 3 | esophageal varices with bleeding | 99.12% | DL |
| 4 | exocrine pancreatic insufficiency | 99.07% | DL |
| 5 | MRCS syndrome | 98.54% | DL |
| 6 | pigmented paravenous retinochoroidal atrophy | 98.33% | DL |
| 7 | familial flecked retinopathy | 97.90% | DL |
| 8 | ectopia lentis-chorioretinal dystrophy-myopia syndrome | 97.82% | DL |
| 9 | retinal dystrophy in systemic or cerebroretinal lipidoses | 97.73% | DL |
| 10 | senile reticular retinal degeneration | 97.71% | DL |
| 11 | Blessig’s cysts | 97.71% | DL |
| 12 | pseudoretinitis pigmentosa | 97.71% | DL |
| 13 | cone dystrophy | 97.68% | DL |
| 14 | genetic macular dystrophy | 97.58% | DL |
| 15 | X-linked retinal dysplasia | 97.46% | DL |
| 16 | progressive bifocal chorioretinal atrophy | 97.45% | DL |
| 17 | varicose disease | 97.38% | DL |
| 18 | retinal drusen | 97.36% | DL |
| 19 | macular degeneration | 97.34% | DL |
| 20 | retinoschisis | 97.30% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.